Study Supports MDxHealth's MGMT Methylation Test as Strong Brain Cancer Prognostic

A new study provides further support for MDxHealth's PredictMDx brain cancer test, which predicts which patients will respond to the alkylating chemotherapy temozolomide.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.